Gastritis Treatment Market Exhibits Higher Growth Prospects during 2018-2026 | Key Players are Otsuka Indonesia PT, AstraZeneca PLC
Gastritis is the irritation, or inflammation, or erosion of the stomach lining. Gastritis may be acute or chronic. The disease may show some symptoms or the symptoms may be dormant. Usually, the symptoms include upper abdominal pain, nausea, and vomiting. Gastritis may lead to stomach tumors, bleeding, and stomach ulcers. Gastritis is usually caused by the bacteria helicobacter pylori or by the use of nonsteroidal anti-inflammatory drugs or NSAIDs. Other possible causes include smoking, cocaine, alcohol, and autoimmune diseases, among others. Treatment of gastritis includes H2 blockers, antacids, or proton pump inhibitors. In an acute gastritis attack, consumption of viscous lidocaine may be of assistance. If H. pylori are present, it may be cured with a combination drug therapy of antibiotics such as clarithromycin and amoxicillin. Gastritis can be cured by proper treatment; hence the demand of gastritis treatment is poised to rise in the foreseeable future.
Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/148
Chronic gastritis is one of the major diseases that affect a significant population of the globe and its prevalence is rising, according to a research report published in National Center for Biotechnology Information. It is estimated that nearly half the population of the world suffers from infection by helicobacter pylori, one of the main agent causing gastritis. There has been a growing concern about the prevalence of the disease around the world. As the disease is a curable disease, demand for its treatment is projected to increase at a steady pace. Technological advancements have brought about a sea change in the treatment of gastritis. According to a report by National Center for Biotechnology Information, patients with atropic gastritis (mucous glad metalapsia waste away) have higher chances of cancer, when compared to other forms of gastritis.
Increasing prevalence of chronic gastritis, especially in the geriatric population offers promising growth for gastritis treatment market
There has been an increasing prevalence of gastritis, especially in the geriatric people around the globe. According to a report by National Center for Biotechnology Information, there were about 90 million new cases of gastritis in 2013. Gastritis and deodenitis (inflammation of the duodenum) caused about 60,000 deaths in 2013. As life expectancy has been increasing, the geriatric population of the globe is also on the rise. According to the same report, the prevalence of gastritis increase with age. Therefore, the demand for gastritis treatment will increase at a steady rate over the forecast period.
North America accounts for the maximum share of the market in the present scenario. Increasing prevalence of gastritis due to high alcohol consumption and unhealthy lifestyle and food habits are some of the reasons for the region’s dominance. However, Asia Pacific is expected to offer a lucrative market for the growth of the gastritis treatment market. The incidences of H pylori infection are high in Asia Pacific and other developing countries. Additionally, the prevalence of gastric adenocarcinomas and multifocal atrophic gastritis is high in these regions. Increase in geriatric population, better awareness about healthcare, and increased health care spending are some of the reasons that will fuel the growth of the gastritis treatment market in this region. Moreover, high occurrence of viral diseases, and autoimmune diseases, and lack of awareness about contagious diseases will propel the growth of the market.
Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/148
The gastritis treatment market is highly fragmented in nature. Many companies are investing heavily in their research and development activities to come up with different treatments of the disease. Companies operating in the gastritis treatment market in the current scenario are Otsuka Indonesia PT, AstraZeneca PLC, Zydus Cadila Healthcare Limited, Novartis AG, and others.